Want to join the conversation?
Pharmaceutical companies, $AMGN and $AGN today announced that a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary endpoints. The study assess the safety and efficacy of ABP 215 when compared with Avastin (bevacizumab) in adult patients suffering from advanced non-squamous non-small cell lung cancer (NSCLC).
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.